Group 1 - The third Tianjin Qihuang Forum and the first Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit opened on November 15, focusing on the theme of "inheritance, innovation, integration, and development" [1] - The event gathered over 200 participants, including academicians, masters of traditional Chinese medicine, scholars, industry experts, and representatives from the traditional Chinese medicine industry chain, promoting deep integration of traditional Chinese medicine and cultural industries [1][3] - The summit featured a three-dimensional model of "academic discussion + industry docking + cultural experience," aiming to inject new momentum into Tianjin's goal of becoming a leading domestic and internationally renowned city for traditional Chinese medicine [1] Group 2 - This year's forum uniquely combined the "Guoyun Traditional Chinese Medicine Cultural Industry Innovation Development Summit," focusing on innovation in the traditional Chinese medicine health industry and upgrading the industry chain, enhancing cross-industry integration and international dissemination [3] - A showcase of ten products, including medicinal food bread and special stamps, was held, with three products highlighted for promotion, attracting significant attention from attendees [3][5] - The forum included discussions on international pathways for promoting traditional Chinese culture, with a presentation by the Deputy Director of the Brand and Market Center of Tianjin Pharmaceutical Daren Tang Group, focusing on the brand's renewal and internationalization efforts [5][6] Group 3 - In a sub-forum on upgrading the traditional Chinese medicine industry chain, the Chief Information Officer of Tianjin Pharmaceutical Daren Tang Group presented on the company's digital transformation and AI strategies, showcasing the results of their AI practices and data innovation since the transformation [8][9]

Core Insights - The recent strategic moves by Gu Sheng Tang, a leading Chinese traditional medicine chain, include a partnership with 1doc in Singapore, the launch of "National Medicine AI Avatar," and collaboration with financial institution AGP, marking a significant shift from product export to service system export in traditional Chinese medicine (TCM) internationalization [2][3][4]. Group 1: Strategic Partnerships - Gu Sheng Tang's collaboration with 1doc involves a shareholding structure where Gu Sheng Tang holds 70% and is responsible for operations, allowing for deep integration of TCM services within the existing Western medical framework [3][4]. - This partnership enables patients to receive integrated TCM and Western medical treatment within the same healthcare ecosystem, enhancing the overall healthcare management experience [4]. Group 2: Policy Alignment and Market Opportunities - The partnership aligns with Singapore's government policy promoting the integration of TCM and Western medicine, particularly the "Traditional Chinese Medicine Integration Sandbox" plan set to launch in 2025 [4][5]. - Singapore's open market and innovative policies provide a high-standard international testing ground for Gu Sheng Tang's TCM practices, which could be replicated in Southeast Asia and globally [5][9]. Group 3: Technological Advancements - The launch of the "National Medicine AI Avatar" aims to standardize and replicate TCM practices, providing an intelligent learning platform for overseas TCM practitioners [7][8]. - This AI system is designed to alleviate the shortage of qualified TCM practitioners abroad and assist in developing precise treatment plans, thereby establishing high-quality TCM service standards in international markets [7][8]. Group 4: Capital Support - Gu Sheng Tang's strategic partnership with AGP will provide direct investment to support its internationalization strategy and AI technology development, enhancing its global healthcare footprint [8]. - The investment from AGP, a spin-off from Singapore's state strategic fund, not only offers financial backing but also access to a network of healthcare resources and insights into international market regulations [8]. Group 5: Industry Implications - The developments signify a paradigm shift in TCM internationalization from isolated cultural exports to a systematic and integrated approach within local healthcare ecosystems [9]. - Singapore serves as an ideal testing ground for this new model, which, if successful, could lead to rapid replication in other international markets [9].